Discover open access scientific publications

Search, annotate, share and cite publications

Publications by P. Blinman

P1.04-11 Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients With NSCLC by Whole Genome Sequencing

Journal of Thoracic Oncology

English

Related publications

P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-Pd-1/Pd-L1

Journal of Thoracic Oncology

English

P1.04-16 Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC With High PD-L1 Expression Tested on Cytology Versus Biopsy Samples

Journal of Thoracic Oncology

English

Pcp61 - Evidence-Based Value of Pd-1 / Pd-L1 Inhibitors in Nsclc: Comparison of Value to Price

English

Automated Image Analysis of NSCLC Biopsies to Predict Response to Anti-Pd-L1 Therapy

Journal for ImmunoTherapy of Cancer

English

P1.04-21 the Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

MA04.07 MicroRNA-Based Liquid Biopsy Combines With PD-L1 Tumor Expression to Predict Response to Immunotherapy in Advance NSCLC Patients

Journal of Thoracic Oncology

English

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology

English

The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response

Klinicka Onkologie

Oncology

2016

English

MA11.06 Prognostic Value of Complement System in NSCLC and Its Association With PD-1 and PD-L1 Expression

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by P. Blinman

P1.04-11 Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients With NSCLC by Whole Genome Sequencing

Related publications

P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-Pd-1/Pd-L1

P1.04-16 Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC With High PD-L1 Expression Tested on Cytology Versus Biopsy Samples

Pcp61 - Evidence-Based Value of Pd-1 / Pd-L1 Inhibitors in Nsclc: Comparison of Value to Price

Automated Image Analysis of NSCLC Biopsies to Predict Response to Anti-Pd-L1 Therapy

P1.04-21 the Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

MA04.07 MicroRNA-Based Liquid Biopsy Combines With PD-L1 Tumor Expression to Predict Response to Immunotherapy in Advance NSCLC Patients

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response

MA11.06 Prognostic Value of Complement System in NSCLC and Its Association With PD-1 and PD-L1 Expression